About This Article
An article published in Clinical Pharmacology & Therapeutics, co-authored by ProSciento and Youngene Therapeutics, discusses findings from a study that examined the effects of two different SGLT inhibitors alongside insulin in individuals with type 1 diabetes. The randomized crossover trial investigated how YG1699 and dapagliflozin influenced glucose levels in type 1 diabetes patients using pump therapy. Results show YG1699 significantly lowered post-prandial glucose levels compared to dapagliflozin, with reduced insulin dose requirements.
Recommended Materials
Articles
A randomized, single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel insulin dimer
Posters
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of INS068 vs Insulin Degludec in Type 1 Diabetes at Steady State: a Phase I, Randomized, Double-blind, Cross-over Trial
Posters
A First in Human, Single Ascending Dose Study to Assess the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of AB101 in Subjects with Type 1 Diabetes​
Related Solutions
Specialized Methods
